Thursday, 15 October 2015
Hall D1 Foyer (Floor 3) (Coex Convention Center)
Anti-tuberculosis (Tb) drugs can cause various adverse drug reactions (ADRs) including hypersensitivity syndrome. Because multiple drugs are concomitantly administered, the detection of culprit drug is essential for successful treatment. Lymphocyte activation test (LAT) is one of the promising methodologies to evaluate delayed drug hypersensitivity, but its role in anti-Tb hypersensitivity remains controversial. A 41-year-old man was referred to allergy clinic with high fever, headache, and skin rash on both arms and legs. He was diagnosed as pulmonary Tb and has started combination anti-Tb drug therapy consisting of isoniazid, rifampicin, ethambutol, and pyrazinamide for 10 days. Body temperature was 38.0 °C. Erythematous maculopapular rash was on both upper and lower extremities and several tender lymph nodes were palpable on cervical area. There were increased levels of aminotransferase (AST) 110 IU/L and alanine transaminase (ALT) 180 IU/L. All anti-Tb drugs were ceased. Patch test showed weak reaction to both rifampin and pyrazinamide. However, only rifampin was strong positive in LAT test. We successfully reintroduced rifampicin by oral desensitization without complication. Our experience suggests that LAT could be helpful to determine culprit drug in poly-pharmacy, especially in anti-Tb drugs.